Measuring the Performance of Markers for Guiding Treatment Decisions

被引:101
作者
Janes, Holly [1 ]
Pepe, Margaret S.
Bossuyt, Patrick M.
Barlow, William E.
机构
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA
基金
美国国家卫生研究院;
关键词
GROWTH-FACTOR RECEPTOR; GENE-EXPRESSION; VALIDATION; CANCER; PREDICTIVENESS; CHEMOTHERAPY;
D O I
10.7326/0003-4819-154-4-201102150-00006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Treatment selection markers, sometimes called predictive markers, are factors that help clinicians select therapies that maximize good outcomes and minimize adverse outcomes for patients. Existing statistical methods for evaluating a treatment selection marker include assessing its prognostic value, evaluating treatment effects in patients with a restricted range of marker values, and testing for a statistical interaction between marker value and treatment. These methods are inadequate, because they give misleading measures of performance that do not answer key clinical questions about how the marker might help patients choose treatment, how treatment decisions should be made on the basis of a continuous marker measurement, what effect using the marker to select treatment would have on the population, or what proportion of patients would have treatment changes on the basis of marker measurement. Marker-by-treatment predictiveness curves are proposed as a more useful aid to answering these clinically relevant questions, because they illustrate treatment effects as a function of marker value, outcomes when using or not using the marker to select treatment, and the proportion of patients for whom treatment recommendations change after marker measurement. Randomized therapeutic clinical trials, in which entry criteria and treatment regimens are not restricted by the marker, are also proposed as the basis for constructing the curves and evaluating and comparing markers.
引用
收藏
页码:253 / W80
页数:8
相关论文
共 25 条
[1]  
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]   Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial [J].
Albain, Kathy S. ;
Barlow, William E. ;
Ravdin, Peter M. ;
Farrar, William B. ;
Burton, Gary V. ;
Ketchel, Steven J. ;
Cobau, Charles D. ;
Levine, Ellis G. ;
Ingle, James N. ;
Pritchard, Kathleen I. ;
Lichter, Allen S. ;
Schneider, Daniel J. ;
Abeloff, Martin D. ;
Henderson, I. Craig ;
Muss, Hyman B. ;
Green, Stephanie J. ;
Lew, Danika ;
Livingston, Robert B. ;
Martino, Silvana ;
Osborne, C. Kent .
LANCET, 2009, 374 (9707) :2055-2063
[3]   Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial [J].
Albain, Kathy S. ;
Barlow, William E. ;
Shak, Steven ;
Hortobagyi, Gabriel N. ;
Livingston, Robert B. ;
Yeh, I-Tien ;
Ravdin, Peter ;
Bugarini, Roberto ;
Boehner, Frederick L. ;
Davidson, Nancy E. ;
Sledge, George W. ;
Winer, Eric P. ;
Hudis, Clifford ;
Ingle, James N. ;
Perez, Edith A. ;
Pritchard, Kathleen I. ;
Shepherd, Lois ;
Gralow, Julie R. ;
Yoshizawa, Carl ;
Allred, D. Craig ;
Osborne, C. Kent ;
Hayes, Daniel F. .
LANCET ONCOLOGY, 2010, 11 (01) :55-65
[4]  
[Anonymous], 2002, Statistical Methods in Diagnostic Medicine
[5]  
[Anonymous], 2003, The Statistical Evaluation of Medical Tests for Classification and Prediction
[6]  
[Anonymous], 2010, NCCN Clinical Practice Guidelines in Oncology Colon Cancer
[7]   Towards validation of statistically reliable biomarkers [J].
Buyse, Marc .
EJC SUPPLEMENTS, 2007, 5 (05) :89-95
[8]   Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [J].
Chung, KY ;
Shia, J ;
Kemeny, NE ;
Shah, M ;
Schwartz, GK ;
Tse, A ;
Hamilton, A ;
Pan, D ;
Schrag, D ;
Schwartz, L ;
Klimstra, DS ;
Fridman, D ;
Kelsen, DP ;
Saltz, LB .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1803-1810
[9]   Use and misuse of the receiver operating characteristic curve in risk prediction [J].
Cook, Nancy R. .
CIRCULATION, 2007, 115 (07) :928-935
[10]   Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].
Cunningham, D ;
Humblet, Y ;
Siena, S ;
Khayat, D ;
Bleiberg, H ;
Santoro, A ;
Bets, D ;
Mueser, M ;
Harstrick, A ;
Verslype, C ;
Chau, I ;
Van Cutsem, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345